Inflammatory bowel disease

This study identifies NR1D1 activation by the experimental drug SR9009 as a potential way to reduce inflammation and improve colon pathology in a mouse model of obesity-associated ulcerative colitis.

Guidelines recommend treating objective inflammation even when symptoms are mild because untreated disease can cause complications; the article describes escalation to risankizumab due to endoscopic inflammation, high...

Based on the title and source metadata, this appears to be a conference abstract related to Inflammatory bowel disease and Research and clinical trials. The original article is from gastroendonews.com.

If confirmed, antibody signatures detectable years before symptoms could help identify people at higher risk for IBD and improve understanding of how the disease begins — a step toward earlier diagnosis or future...

Transition from pediatric to adult IBD care is a high-risk period; structured programs and better communication can improve adherence and reduce relapse and hospitalization risk for young people with IBD.

Real-world data show how mirikizumab performs outside clinical trials, especially in patients previously exposed to multiple advanced therapies. That can help patients and clinicians weigh expectations for effectiveness...

Oat beta-glucan is a dietary fibre with prebiotic properties; the review suggests potential benefits seen in animal studies but shows human evidence is limited. Patients and clinicians may care because dietary fibres are...

Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from djournal.com.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Upadacitinib. The original article is from Przeglad gastroenterologiczny.

Methotrexate is commonly used in IBD, often with biologics, but real‑world data on how long patients stay on it, typical dosing, and safety in large contemporary cohorts are limited.

Fear of movement was more common and more severe in people with ulcerative colitis in this study. Addressing kinesiophobia could help increase physical activity and improve function and quality of life for people with...

This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...

An externally validated, simple prediction score could help identify patients unlikely to need early aggressive treatment and inform shared decision-making about monitoring and therapy.

Life satisfaction and social/work impacts are central to daily functioning for people with IBD. Knowing which social factors relate to lower satisfaction can help patients, caregivers, and clinicians spot who may need...

Dietary therapy (CDED + PEN) was associated with longer remission when families adhered well; since adherence varies, support from a dietitian matters for keeping children in remission.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and JAK inhibitor. The original article is from Journal of Crohn's & colitis.

This paper systematically catalogs drugs that have been reported with new or worsening IBD in two large pharmacovigilance databases. Knowing which medications generate strong reporting signals can help clinicians and...

A patient-centered journey map identifies changing symptom, psychological, and social needs at different stages of Crohn's disease. That can help clinicians and care teams target education, mental-health support, and...

People with ulcerative colitis may be interested because ferulic acid is a plant-derived compound that, in lab and animal studies, appears to reduce gut inflammation, support the intestinal barrier, and positively...

Kidney and urinary problems (acute or chronic kidney injury and kidney stones) occurred in a notable minority of IBD patients in this study and were linked to prior IBD surgery, extensive UC, and cardiometabolic...

Active IBD was linked to higher risk of RSV infection and more severe respiratory outcomes in this large observational study. That could be relevant for prevention and monitoring during periods of active disease.

This study describes a lab-stage engineered probiotic–silver nanoparticle therapy that reduced inflammation and promoted colon repair in an animal colitis model; it highlights new molecular targets (Wnt signaling and...

Subcutaneous infliximab could offer children with IBD a more convenient dosing route with higher, steadier drug levels while maintaining remission. Insurance and labeling barriers affected access in this US cohort.

Strictures raise the risk that food will get stuck and cause a dangerous blockage. Simple changes to texture, portion size, and eating habits can lower that risk and help you keep a varied diet.

For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...

The work suggests a fungus-derived metabolite can reduce experimental colitis through AhR and NF-κB pathways, highlighting a potential new direction for microbiome‑based therapies or postbiotics that could eventually...

Identifies a redox-sensitive NOX1–ROS–IκBζ pathway that may sustain intestinal inflammation in IBD and points to a new molecular target for future therapies.

LCH can present like perianal Crohn's disease and may be missed if biopsies and molecular testing are not performed. Correct diagnosis changes treatment and prompts systemic staging for other malignancies.

The study found disease-specific antibody changes years before IBD diagnosis, suggesting possible early biomarkers and new clues about how Crohn's disease and ulcerative colitis begin.

Cure8 indexed source-provided abstract text from JAMA, but this record did not meet the threshold for a full Cure8 brief. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Procedures and surgery.

FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...

Based on the title and source metadata, this appears to be a clinical study related to Inflammatory bowel disease and Complications. The original article is from Journal of Investigative Dermatology.

The study identifies a specific polysaccharide fraction (VPS-30) that reduced inflammation and improved gut barrier markers in cell and mouse models of colitis, suggesting a possible new functional-food lead for...

Researchers and clinicians are exploring cGAS/STING as a novel immune pathway linked to mucosal barrier function and inflammation in UC. Modulators of this pathway could become future targeted treatments, so patients and...

Identifies macrophage-linked genes (CCL3, CCL4, JUNB) that are strongly upregulated in ulcerative colitis and may help explain immune-cell remodeling in the colon. These genes could serve as biomarkers or starting points...

This trial tests whether people with UC in deep remission can safely stop JAK inhibitor therapy — potentially reducing long-term exposure and associated safety concerns while preserving disease control and quality of...

This Phase 2a trial tested a new investigational drug, tulisokibart, in people with moderately to severely active Crohn’s disease who have not done well on prior therapies — so patients and clinicians watching new...

The study will prospectively evaluate how often dysplasia occurs, how lesions look and behave after endoscopic resection, and what factors predict local or distant recurrence—information that could change surveillance...

The FDA label for dexamethasone explicitly lists regional enteritis (Crohn's disease) and ulcerative colitis among its gastrointestinal indications, and provides dosing guidance and steroid-equivalent tables that are...

The systems view could explain limits of single-cytokine therapies and point toward multi-layer, precision approaches that better match a patient’s specific immune, genetic, and microbial context.

The editorial outlines treatment strategies that could affect whether a person with ASUC avoids colectomy, highlights the importance of getting adequate infliximab exposure, and summarizes emerging drug classes that may...

Exercise is a low-cost, accessible intervention that may improve quality of life and reduce symptoms in people with IBD. This pooled analysis suggests some exercise types — especially regular continuous aerobic exercise...

The study links ER stress and defective autophagy to increased claudin-2 and tight-junction dysfunction—mechanisms relevant to barrier loss in IBD. Targeting this pathway could eventually inform therapies to preserve...

Cure8 could only read part of this source from dignitymemorial.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and...

Detecting Crohn’s recurrence after bowel surgery is important because recurrence can occur without symptoms. A reliable non-invasive test like intestinal ultrasound could reduce the need for repeated colonoscopies and...

For people with moderate–severe Crohn’s disease who failed anti‑TNF drugs, this trial suggests risankizumab may achieve higher corticosteroid‑free clinical and endoscopic remission than ustekinumab, which could mean...

Findings help patients and surgical teams set expectations before laparoscopic ileocecal resection: certain disease patterns (fistulizing) and older age raise the chance of conversion, which can increase length of stay...